Press Release
2021-12-09
Avistone Completes $200 Million-plus Fundraising, with Vivo Capital as the Lead Investor
On December 9, 2021, Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd ("Avistone") announced the closure of Series A funding, raising over $200 million.
View Details
Media Coverage
Acceptance of Avistone's application for launch of MET inhibitor Vebreltinib enteric capsule (PLB-1001) in China
2022-09-28
Avistone recently announced the application by its subsidiary Purun'ao Biotechnology for the launch of its Vebreltinib enteric capsule. The application has been accepted on September 24 by the National Medical Products Administration for priority review. The proposed application of Vebreltinib is for the treatment of partial late-stage or metastatic NSCLC patient with Mesenchymal-epithelial transition factor (MET) Exon 14 skipping.
Here comes the ranking list! Unveiling the Top 10 finalists in biomedical field for 2022 Zhongguancun International Frontier Technology Innovation Competition
2022-09-15
On September 15, 2022, the finals for biomedical section in the 2022 Zhongguancun International Frontier Technology Innovation Competition was held in Zhongguancun Lif Sciences Park in Beijing's Changping District. Ten technology companies emerged from the rank and file and were named Top 10 finalists.
Company Profile
©2022 Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd.
京ICP备2020040683号-2